Because early detection is the key to successful outcomes, this practice has incorporated ViziLite Plus, a technology cleared by the FDA, into the standard of care of the practice, to ensure that you receive the most comprehensive oral cancer screening possible.
The newest tool in the fight against oral disease is the ViziLite® Plus oral lesion identification and marking system.
ViziLite Plus makes oral screening more comprehensive than ever before and is indicated for use in individuals at increased risk of oral cancer. If ViziLite reveals an abnormality, TBlue can be used to mark suspicious lesions for further evaluation.
ViziLite Plus is a simple, painless and non-invasive technology that improves the doctor's ability to visualize, mark, evaluate and monitor suspicious areas at their earliest stages, before they can progress to something far more serious, and potentially life-threatening. ViziLite Plus helps the doctor see what he/she may not see with the unaided eye.
Look for any abnormalities
Swab area clean
Swab area with TBlue
Re-examine the area
About Oral Cancer
Most people are surprised to learn that one American dies every hour from oral cancer; a death rate that has remained virtually unchanged for more than 40 years. In fact, recent statistics published by the American Cancer Society indicate that while the incidence and death rates for cancers overall has decreased, the incidence of oral cancer has increased by 5.5% and the death rate has increased by 1.5%
Oral cancer is far too often discovered in late stage development, the primary reason for the consistently high death rate. Oral cancer treatment often results in disfiguring effects on patients, and can seriously compromise their quality of life. Early detection and diagnosis can make a tremendous difference in life expectancy; oral cancer is 90% curable when found in its early stages. Unfortunately, 70% of oral cancers are diagnosed in the late stages, III and IV, leading to a five-year survival rate of 57%.
